Pfizer, BMS Aim To Block Generic In Blood Thinner IP Fight
Pfizer and a subsidiary of Bristol Myers Squibb have hit back at an attempt by Teva to invalidate patents for development of a blockbuster blood thinner, saying the generic drugmaker's planned...To view the full article, register now.
Already a subscriber? Click here to view full article